The FDA has approved obinutuzumab (Gazyva) in combination with chemotherapy, followed by obinutuzumab alone, for the first-line treatment of patients with advanced follicular lymphoma, according to Genentech, the manufacturer of the therapy.
The FDA previously approved obinutuzumab for use in combination with bendamustine for patients with follicular lymphoma who have received prior therapy.
FDA Approves Genentech’s Gazyva for Previously Untreated Advanced Follicular Lymphoma. https://www.gene.com/media/press-releases/14691/2017-11-16/fda-approves-genentechs-gazyva-for-previ. Accessed November 16, 2017.
... to read the full story